Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar

Renzo Mazzarotto1, Nicola Simoni1*, Stefania Guariglia2, Gabriella Rossi1, Renato Micera1, Riccardo De Robertis3, Alessio Pierelli2, Emanuele Zivelonghi2, Giuseppe Malleo4, Salvatore Pailella4, Roberto Salvia4, Carlo Cavedon2, Michele Milella5 and Claudio Bassi4

1 Department of Radiation Oncology, University of Verona Hospital Trust, Verona, Italy, 2 Department of Medical Physics, University of Verona Hospital Trust, Verona, Italy, 3 Department of Radiology, University of Verona Hospital Trust, Verona, Italy, 4 Department of General and Pancreatic Surgery, University of Verona Hospital Trust, Verona, Italy, 5 Department of Oncology, University of Verona Hospital Trust, Verona, Italy

Background and Objective: To assess the dosimetric feasibility of a stereotactic body radiotherapy (SBRT) dose escalated protocol, with a simultaneous integrated boost (SIB) and a simultaneous integrated protection (SIP) approach, in patients with locally advanced pancreatic cancer (LAPC).

Material and Methods: Twenty LAPC lesions, previously treated with SBRT at our Institution, were re-planned. The original prescribed and administered dose was 50/30/25 Gy in five fractions to PTVsib (tumor-vessel interface [TVI])/PTVt (tumor volume)/PTVsip (overlap area between PTVt and planning organs at risk volume [PRVoars]), respectively. At re-planning, the prescribed dose was escalated up to 60/40/33 Gy in five fractions to PTVsib/PTVt/PTVsip, respectively. All plans were performed using an inspiration breath hold (IBH) technique and generated with volumetric modulated arc therapy (VMAT). Well-established and accepted OAR dose constraints were used (D0.5cc < 33 Gy for luminal OARs and D0.5cc < 38 Gy for corresponding PRVoars). The primary end-point was to achieve a median dose equal to the prescription dose for the PTVsib with D98 ≥ 95% (95% of prescription dose is the minimum dose), and a coverage for PTVt and PTVsip of D95 ≥ 95%, with minor deviations in OAR dose constraints in < 10% of the plans.

Results: PTVsib median (± SD) dose/D95/conformity index (CI) were 60.54 (± 0.85) Gy/58.96 (± 0.86) Gy/0.99 (± 0.01), respectively; whilst PTVt median (± SD) dose/D95 were 44.51 (± 2.69) Gy/38.44 (± 0.82) Gy, and PTVsip median (± SD) dose/D95 were 35.18 (± 1.42) Gy/33.01 (± 0.84) Gy, respectively. With regard to OARs, median (± SD) maximum dose (D0.5cc) to duodenum/stomach/bowel was 29.31 (± 5.72) Gy/25.29 (± 6.90) Gy/27.03 (± 5.67) Gy, respectively. A minor acceptable deviation was found for a single plan (bowel and duodenum D0.5cc=34.8 Gy). V38 < 0.5 cc was achieved for all PRV luminal OARs.
INTRODUCTION

The results of standard dose radiation therapy (RT) in locally advanced, unresectable pancreatic cancer (LAPC) are unsatisfactory. Conventional RT strategies (conventionally fractionated radiation therapy [CFRT]) have a modest impact on long-term tumor control and survival. Indeed, the randomized LAP-07 Phase III trial failed to demonstrate improvement in overall survival (OS) in LAPC patients by adding CFRT (54 Gy/30 fractions with concurrent capcitabine) after neoadjuvant chemotherapy versus continuation of chemotherapy alone (1). However, RT was associated with a decrease in local progression (32% vs 46%, p = 0.03) without increasing grade ≥ 3 toxicity. Four other randomized trials have compared CFRT, concomitant with chemotherapy, versus chemotherapy alone in LAPC, with interlocutory results: two trials supported a chemo-radiation approach (2, 3), while two did not (4, 5).

Although metastatic disease represents the main cause of morbidity and mortality in LAPC, about one third of patients die from complications related to local tumor progression (6). Moreover, Crane et al. found that local tumor progression was from complications related to local tumor progression (6). Despite this, the administration of ablative doses to the tumor-vessel interface (PTV_{sv}) can sterilize the tumor (8). The SIB volume (PTV_{sib}) was created by lowering the dose to 25 Gy on the overlap area between the PTV_t and the planning organs at risk volume (PRV_{OARs}). No acute or late grade ≥ 3 adverse events related to SBRT were observed. Moreover, 34.4% of locally advanced patients received surgical resection. Nonetheless, the performed dosimetric evaluation showed a predominant incidence of in-field failure, with a progression median dose of 40.42 Gy. These data support the need to further investigate the possibility of administering higher doses of RT, using this SBRT approach, in order to improve oncological outcomes in LAPC.

Based on this background, we aimed at performing a dosimetric study to assess the feasibility of SBRT with a SIB/SIP dose escalated protocol in LAPC, to administer higher doses to the tumor, while preserving OAR dose constraints.

MATERIALS AND METHODS

Study Design

Twenty patients with LAPC, treated at our Institution with SBRT in 5 consecutive daily fractions using a SIB/SIP approach (50/30/25 Gy to PTV_{sib}/PTV_t/PTV_{sip}, respectively) (15), were re-planned for a dose escalation proposal. Patients were randomly selected from a prospective collected database. The final goal of this dosimetric evaluation study was to escalate the dose up to 60/40/33 Gy in five fractions to PTV_{sib}/PTV_t/PTV_{sip}, respectively (Table 1). If the planning objectives were not met at this dose level (level IV), the prescription dose would be progressively reduced to the inferior levels (level III, II or I), until the pre-established planning objectives were achieved. The biologically effective dose (BED) was used to compare the different dose levels among each other, and with other recommended fractionations adopted in the clinical practice. The BED was calculated using the linear quadratic formula: 

$$\text{BED} = nD \times [1 + d/(\alpha/\beta)],$$

where $n$ is the total number of fractions and $d$ is the dose per fraction (Gy). Standard $\alpha/\beta$ ratio for tumors ($\alpha/\beta = 10$) and normal tissues ($\alpha/\beta = 3$) was chosen. Dose constraints to organs at risk (OARs) were selected according to recently published guidelines (16). In particular, a $D_{0.5cc} < 33$ Gy for luminal OARs and a $D_{0.5cc} < 38$ Gy for corresponding PRVs were adopted.

SBRT Protocol and Planning

Patients were immobilized in a supine position with arms over the head, on a custom-made Vac-Lok™ cushion to optimize set-up reproducibility. Fiducial markers (3–4 gold seeds), using an eco-endoscopic procedure (EUS), were placed prior to

Conclusions: In LAPC patients SBRT, with a SIB/SIP dose escalation approach up to 60/40/33 Gy in five fractions to PTV_{sib}/PTV_t/PTV_{sip}, respectively, is dosimetrically feasible with adequate PTVs coverage and respect for OAR dose constraints.

Keywords: stereotactic body radiotherapy, pancreatic cancer, locally advanced, dose escalation, ablative dose
simulation computed tomography (CT). To manage breathing-induced tumor motion, an inspiration breath hold (IBH) technique was used. Briefly, patients were trained to maintain a regular respiratory cycle, using the real-time position management® system (RPM) (Varian Medical Systems, Palo Alto, CA) as visual guide. At a comfortable inspiration phase of the respiratory cycle, patients were asked to hold their breath (IBH) to allow CT scan acquisition. After a first unenhanced IBH scan, a multi-phase contrast-enhanced simulation CT was performed (Figure 1), including the acquisition of an additional 3 to 4 contrast-enhanced IBH scans.

An integrated gross tumor volume (GTV) was defined as the envelope of the GTVs delineated on each CT scan. An GTV-to-PTV margin of 3 mm was applied to generate the PTV tumor (PTVt). For critical OARs such as the duodenum, stomach and bowel, a 3 mm expansion PRV oars was defined. The simultaneous protection volume (PTV sip) was generated by the intersection of the PTVt and the PRV oars. A PTV high dose (PTVsib) was generated to encompass the tumor-vessel interface (TVI). Critical vessels (e.g. superior mesenteric artery/vein, portal vein, celiac artery) inside the GTV were contoured for the whole circumference and then expanded by 3 mm to generate

| TABLE 1 | SBRT standard dose and levels of SBRT dose escalation proposal*. |
|-----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                 | Standard Dose (Gy/frac)     | Level I                     | Level II                    | Level III                   | Level IV                    |
| PTVt            | 30 Gy (6 Gy)                | 32.5 Gy (6.5 Gy)            | 35 Gy (7 Gy)                | 37.5 Gy (7.5 Gy)            | 40 Gy (8 Gy)                |
|                 | BED10 48 Gy                 |                             |                             |                             |                             |
| PTV oars        | 50 Gy (10 Gy)               | 52.5 Gy (10.5 Gy)           | 55 Gy (11 Gy)               | 57.5 Gy (11.5 Gy)           | 60 Gy (12 Gy)               |
|                 | BED10 100 Gy                |                             |                             |                             |                             |
| PTV sip         | 25 Gy (5 Gy)                | 27.5 Gy (5.5 Gy)            | 30 Gy (6 Gy)                | 32.5 Gy (6.5 Gy)            | 33 Gy (6.6 Gy)§             |
|                 | BED10 37.5 Gy               |                             |                             |                             |                             |
|                 | BED10 66.67 Gy              |                             |                             |                             |                             |

*An increase of 2.5 Gy for the 3 PTVs was planned for each dose level.
§The prescribed dose is not increased further in order not to conflict with OARs dose constraints.

FIGURE 1 | (A, B) Axial pancreatic CT-simulation phase images show hypovascular body mass of pancreas, delineated as gross tumor volume (GTV, orange) with encasement of celiac axis (CA, green), common hepatic artery (CHA, cyan), and superior mesenteric-portal venous confluence (SMPV, violet). (C) Arterial coronal CT-simulation image shows lesion encasing CA. (D) Coronal CT-simulation image highlights the SMPV system occlusion and portal vein infiltration.
the PTV\textsubscript{sub}. If necessary, this PTV\textsubscript{sub} was contracted to respect a minimal distance of 5 mm from the PTV\textsubscript{sup} (Figures 2A, B).

All SBRT plans were calculated for a TrueBeam\textsuperscript{®} medical linac (Varian Medical System, Palo Alto, CA) equipped with a high definition multileaf collimator (HDMLC-120) and using a Volumetric Modulated Arc Therapy (VMAT) technique (Figures 2C, D). A photon energy of 6MV, flattening filter free (FFF) technique, dose rate 1400 MU/min, three arc configuration and anisotropic analytic algorithm (AAA) were used for planning and dose calculation in the Eclipse\textsuperscript{®} treatment planning system (Varian Medical Systems, Palo Alto, CA). All the plans have been calculated using the standard inverse optimization process, based on Dose-Volume Histogram (DVH) parameters.

All the plans were prepared to be managed, during the delivery phase, using an IBH respiratory gating system (RPM\textsuperscript{®} Varian Medical Systems, Palo Alto, CA) with daily IBH cone-beam CT (CBCT) image registration. IBH-CBCTs acquisition allows high quality daily scans with minimized motion artefacts, that, along with the presence of fiducial markers, improves the day-to-day target position verification and reduces inter and intra-fractions errors.

**Study End-Points**

The main objective of the study was to ensure adequate coverage of the PTV\textsubscript{sub}, simultaneously respecting dose constraints to OARs. In particular, coverage goals for the targets were:

- median dose equal (± 2%) to the prescription dose for PTV\textsubscript{sub}
- D\textsubscript{98}≥95% (95% of prescription dose is the minimum dose) for PTV\textsubscript{sub}
- maximum point dose of 107% inside PTV\textsubscript{sub}
- D\textsubscript{95}≥95% for PTV\textsubscript{t} and PTV\textsubscript{sup}

The goal for OARs was a minor deviation in dose constraints in < 10% of the plans.

Dose volume histograms (DVHs) were generated for each plan, and multiple dosimetric parameters for PTVs (PTV\textsubscript{t}, PTV\textsubscript{sub}, and PTV\textsubscript{sup}) and OARs (duodenum, stomach, small and large bowel, spinal cord, liver, kidneys, and PRVs) were evaluated. The conformity index (CI) was defined as the volume encompassed by the 95% isodose divided by the PTV volume. CI was evaluated for PTV\textsubscript{sub} alone, since this index is formulated based on the paradigm of
uniform dose prescription, which is not the case for this SBRT treatment with SIB/SIP approach.

RESULTS

Study Population

Baseline characteristics of the 20 patients included in this study are outlined in Table 2. All patients had locally advanced pancreatic carcinoma (LAPC), and were considered unresectable due to vascular involvement.

SBRT Planning and PTVs Coverage

All the SBRT plans met the predetermined target coverage objectives. Table 3 describes the results of the treatment plan analysis of the dose escalation proposal (60/40/33 Gy in five fractions to PTV<sub>sub</sub>/PTV<sub>t</sub>/PTV<sub>sip</sub>, respectively). PTV<sub>sub</sub> median dose, D<sub>sub</sub>, and CI were 60.54 Gy (± SD 0.85), 58.96 Gy (± SD 0.85), and 0.99 (± SD 0.01), respectively. The median dose was 44.51 Gy (± SD 2.69) for PTV<sub>t</sub>, and 35.18 Gy (± SD 1.42) for PTV<sub>sip</sub>. For PTV<sub>sub</sub>, a D<sub>100</sub>≥95% was reached in 18 (90%) plans, while D<sub>sub</sub>≥95% was obtained in all cases (100%). A maximum dose of less than 107% for PTV<sub>sub</sub> was maintained in every plan.

OAR Constraints

With regard to OARs, mean maximum dose (D<sub>0.5cc</sub>) to duodenum/stomach/bowel was 29.31 Gy (± SD 5.72)/25.29 Gy (± SD 6.90)/27.03 Gy (± SD 5.67), respectively. Table 4 describes treatment plans analysis for OARs. A minor acceptable deviation was observed in a single plan, with bowel and duodenum D<sub>0.5cc</sub> = 34.8 Gy (Figure 3). V38 < 0.5 cc was achieved for all PRV luminal OARs.

DISCUSSION

Stereotactic body radiation therapy (SBRT) has demonstrated promising results in locally advanced, unresectable pancreatic cancer (LAPC). However, durable local control (LC) remains challenging, and higher biologically effective doses (BED<sub>10</sub>) are suggested to achieve tumor ablation. Advances in radiation delivery techniques, image-guidance (IGRT) and treatment planning, may allow for dose escalation to levels not previously achievable, potentially improving LC and survival. The results of the present study demonstrate that for LAPC, a 5-fraction SBRT with a SIB/SIP dose escalation protocol up to 60/40/33 Gy to PTV<sub>sub</sub>/PTV<sub>t</sub>/PTV<sub>sip</sub>, respectively, is dosimetrically feasible with adequate PTVs coverage and respect for OAR dose constraints.

The clinical rationale for this dosimetric study derives from our current experience with SBRT in pancreatic cancer. In a series of 59 patients treated with SBRT with SIB/SIP at our Institution, we found no G3 toxicities, but a predominant

### Table 2 | Baseline characteristics of locally advanced pancreatic cancer patients (n = 20).

| Age, y, median (range) | 65 (39–73) |
|------------------------|------------|
| Gender, male, n (%)    | 13 (65)    |
| Tumor diameter (mm), (median, min-max) | 31 (20–51) |
| Primary Site           |
| Head                   | 13 (65)    |
| Body                   | 7 (35)     |
| Pre-SBRT chemotherapy   |
| Gemcitabine + nab-Paclitaxel, n (%) | 11 (55) |
| FOLFIRINOX, n (%)       | 9 (45)     |
| Biliary Stent, yes, n (%) | 7 (35) |
| Ca 19-9 values (U/ml)   |
| At diagnosis, mean (SD) | 601 (± 328) |
| Pre-SBRT, mean (SD)     | 54 (± 60)  |
| Involved vessels        |
| CA involvement, n (%)   | 9 (45)     |
| CHA involvement, n (%)  | 7 (35)     |
| SMA involvement, n (%)  | 11 (55)    |
| PV/SMV involvement, n (%) | 8 (40) |

*FOLFIRINOX, fluorouracil, leucovorin, oxaliplatin;
CA, celiac artery; CHA, common hepatic artery; SMA, superior mesenteric artery; PV, portal vein; SMV, superior mesenteric vein.

### Table 3 | Treatment plan analysis for PTVs*.  

| PTV<sub>sub</sub> | Median volume | D<sub>median</sub> (60 Gy ± 2%) | D<sub>max</sub> <107% | D<sub>sub</sub> ≥95% | D<sub>sub</sub> ≥95% | D<sub>sub</sub> | CI | Results, Mean (± SD) |
|-------------------|---------------|-------------------------------|-------------------|-----------------|-----------------|----------------|---|-------------------|
|                   |               | 8.1 cc (5.3–41.2)             | 60.54 (± 0.85) Gy | 103.7 (± 1.25) % | 97.5 (± 1.00) % | 100%             |    |                   |
| PTV<sub>t</sub>   | Median volume | 42.5 cc (21.3–118)            | 44.51 (± 2.69) Gy | 96 (± 0.80) %   | 59.39 (± 0.93) Gy | 5.9 cc (2.2–80.9) |    |                   |
|                   | D<sub>median</sub> | -                           | -                 | -               | -               | -               |    |                   |
|                   | D<sub>max</sub> | 35.18 (± 1.42) Gy             | -                 | -               | -               | -               |    |                   |
|                   | D<sub>sub</sub> | 100%                          | -                 | -               | -               | -               |    |                   |

*60/40/33 Gy in five daily fractions to PTV<sub>sub</sub>/PTV<sub>t</sub>/PTV<sub>sip</sub>, respectively.

**|Median volume (range).
incidence of in-field failures (15). Based on these results, we evaluated the opportunity and feasibility of a dose escalation protocol, with the aim of improving the clinical outcomes of the aforementioned SBRT approach. In this regard, a recent MDACC study provided a remarkable roadmap to achieve a dose escalation up to 60 Gy in SBRT for LAPC (17).

The currently recommended dose in pancreatic SBRT is 33–40 Gy in five fractions (BED$_{10}$ = 54.78–72 Gy) (18), instead BED$_{10}$ of not less than 100 Gy is generally advocated to maximize the RT therapeutic effect and improve oncological outcomes (19). These doses are presumably necessary if the goal of SBRT is to achieve results comparable to surgery. However, when SBRT is applied to pancreatic tumors, the prescription of such high doses is challenging due to the proximity of critical OARs (e.g. duodenum, stomach and bowel), and serious late toxicity, such as perforation, stenosis, and ulcer with bleeding, could be expected (14). In our experience, the use of the SIP in pancreatic SBRT had presumably prevented serious damage to OARs. Considering that less than 10% of patients with LAPC are suitable for surgery after neoadjuvant therapy (20), the administration of such high doses should be as safe as possible. Thus, the use of this 3-dose level SBRT approach can certainly allow to maximize the therapeutic window. Indeed, a clinically acceptable plan was obtained for all patients, with an excellent PTVs$_{ib}$ coverage (D$_{98}$ ≥ 95% reached in all plans) and adequate respect for OAR dose constraints (a minor acceptable deviation was observed in a single plan for bowel and duodenum D$_{0.5cc}$ = 34.8 Gy), even when the prescribed dose corresponds to 60 Gy and 33 Gy to the TVI and SIP volume, respectively. Noteworthy, the median dose of PTV tumor (PTV$_{t}$) at level IV of the dose escalation proposal was 44.51 (± 2.69) Gy, corresponding to a BED$_{10}$ of 84.13 (± 2.83) Gy. Therefore, as a consequence of the high dose gradient within the tumor target, the PTV$_{t}$ absorbed dose would be consistently higher than the one expected (40 Gy for a BED$_{10}$ of 72 Gy), potentially further increasing the final local effect of the SBRT.

Organ motion control is crucial for a dose escalation proposal. Our standard approach involves the use of the

| TABLE 4 | Treatment plans analysis for OARs$^*$. |
| Organ | Parameter | Constraints | Minor Variation | Major Variation | Results (mean ± SD) |
|-------|-----------|-------------|----------------|----------------|--------------------|
| Duodenum | D$_{max}$ (0.5 cc) | <33 Gy | ≤35 Gy | >35 Gy | 29.31 ± 5.72 |
| | V$_{30Gy}$ | <5 cc | 5–10 cc | >10 cc | 20.52 ± 6.80 |
| Stomach | D$_{max}$ (0.5 cc) | <33 Gy | ≤35 Gy | >35 Gy | 27.03 ± 5.67 |
| | V$_{30Gy}$ | <5 cc | 5–10 cc | >10 cc | 20.52 ± 6.80 |
| Bowel$^a$ | D$_{max}$ (0.5 cc) | <33 Gy | ≤35 Gy | >35 Gy | 33.68 ± 6.51 |
| | V$_{30Gy}$ | <5 cc | 5–10 cc | >10 cc | 20.52 ± 6.80 |
| PRV duodenum | D$_{max}$ (0.5 cc) | <33 Gy | ≤35 Gy | >35 Gy | 29.51 ± 8.01 |
| PRV stomach | D$_{max}$ (0.5 cc) | <33 Gy | ≤35 Gy | >35 Gy | 32.31 ± 4.37 |
| PRV bowel | D$_{max}$ (0.5 cc) | <33 Gy | ≤35 Gy | >35 Gy | 12.33 ± 2.00 |
| Liver | V$_{12Gy}$ | <40% | ≤50% | >50% | 5.42 ± 5.3 |
| Kidneys (combined) | V$_{12Gy}$ | <25% | ≤25% | >25% | 5.34 ± 5.5 |

SD, standard deviation; cc, cube centimeter; Gy, gray; PRV, planning organ at risk volume.
$^*60/40/33$ Gy in $5$ daily fractions to PTV$_{spl}$/PTV$_{t}$/PTV$_{sip}$, respectively.
$^a$Small and large bowel.

FIGURE 3 | (A) Dose distribution (color wash) and (B) dose-volume histogram (DVH) for the single SBRT plan showing a minor acceptable deviation for bowel and duodenum (D$_{0.5cc}$ = 34.8 Gy). As shown in panel A, the anatomy for this lesion is rather unfavorable, with the simultaneous protection volume (PTV$_{spl}$, dark green), surrounded for almost two thirds of the circumference by the PRVs. The following structures are shown: tumor planning target volume (PTV$_{t}$, blue), duodenum (black), and bowel (light green). The Planning at Risk Volume (PRV$_{card}$) are shown with same color on axial image.
abdominal compressor (15). Indeed, in a study evaluating the effect of abdominal compression in pancreatic cancer, it was observed that with the use of this technique a cranio-caudal (CC) margin of 5 mm was adequate to encompass the tumor target motion in more than 90% of the patients (21). More recently, Campbell et al. compared compression and gating for pancreatic SBRT: the average motion in CC direction was 8.5 mm with abdominal compression, and 5.5 mm with respiratory gating (22). Similarly, the use of a breath hold technique can minimize the required PTV expansion compared with treatment during free breathing or with the use of abdominal compression (23). As a whole, these results suggest that respiratory gating and breath hold may be the best choice for organ motion management in pancreatic SBRT, in particular if a dose escalated approach is planned. Nevertheless, pancreatic region-dependent variations in respiratory induced organ motion, and their effects on motion control approach, have been described (24). In particular, motion mitigation techniques resulted less effective in the tail region, with no difference between the use of abdominal compression versus respiratory gating, probably due to the larger positional error in the tail region based on the abdominal wall surrogate. Taking this into consideration, in the present study no tail lesions were included for the dose escalated proposal, hence the results are not applicable to the tumors of this pancreatic region. In the near future, the use of Magnetic Resonance-guided Radiation Therapy (MRgRT) will allow a daily online adaptation of the treatment plan, immediately before each fraction delivery, to optimize the dose distribution based on target and OAR anatomy, as well as a real-time management of the organ motion (25).

Another point of discussion is SBRT target delineation. Recent guidelines provide a clear definition for the primary GTV and tumor-vessel interface (TVI), aiming to standardize treatment volumes (16). Moreover, in our and other experiences reported in the literature, a SIB technique was used for clinical dose painting to deliver higher doses to a specific area of the tumor (15, 26–31). Table 5 summarizes studies describing the use of SBRT with a SIB approach in pancreatic cancer, underlining the variability among authors in the definition of the SIB volume. In the present study, the PTV_sib was generated to encompass the TVI, in order to simplify the comparison with the plans evaluated and approved in our clinical practice. Furthermore, the vascular encasement, represented by the TVI is the main obstacle to plan and achieve a curative resection for LAPC. Since the SBRT technique can be easily integrated into a total neoadjuvant therapy (TNT), an ablative boost to the TVI could maximize the possibility of a conversion to surgery. In this regard, to better define TVI, the integration of MRI images with a contrast-enhancement CT-simulation scan, could offer a higher definition of tumor relationship with neighboring vessels and a greater accuracy of target delineation (32).

This study has potential limitations. The sample size is relatively small, and although a reasonable variety of locally advanced diseases was included, not all possible tumor characteristics and anatomical heterogeneity were represented. Therefore, some patients who meet the inclusion criteria for this dose escalated SBRT in the “dosimetric reality”, may not be suitable for the same dose escalation in “real life”. Furthermore, the dose constraints used are based on a commonly accepted consensus for SBRT, however validation in the clinical practice is necessary, thus the inclusion of patients in a clinical trial is strongly recommended. Finally, not all LAPC patients are candidates for SBRT. Exclusion criteria for SBRT are usually as follows: tumor > 6 cm in greatest dimension, nodal spread that cannot be included in the SBRT target volume, and tumors infiltrating the stomach or duodenum. For these patients, an alternative 15-fractions hypofractionated ablative radiation therapy approach may be investigated (Supplementary Material).

In conclusion, this study demonstrates that a SBRT dose escalation protocol with a SIB/SIP approach for LAPC up to 60/40/33 Gy in five fractions to $PTV_{sib}/PTV/PTV_{sip}$, respectively, is feasible with adequate target coverage and without unacceptable increased OAR exposure. Based on this dosimetric analysis, a Phase II dose escalated trial is ongoing at our Institution.

**TABLE 5** | Studies using SBRT with Simultaneous Integrated Boost (SIB) for pancreatic cancer.

| Reference | Fractions (n) | PTV definition | PTV dose | SIB target | SIB dose |
|-----------|---------------|----------------|---------|------------|---------|
| Chuong et al. (26) | 5 | PTV = entire tumor + 3–5 mm | 25 Gy | TVI (region of vessel abutment/encasement) | 35 Gy |
| Mellon et al. (27) | 5 | PTV = GTV (plus motion) + 3–5 mm | 30 Gy | TVI (areas of vessel involvement by tumor) | 40 Gy |
| Shaib et al. (28) | 3 | PTV = GTV with at-risk area of microscopic spread + 5 mm | 36 Gy | PM = volume between the posterior 1 cm of GTV and mesenteric vessel/retroperitoneal soft tissue | 45 Gy |
| Holyoke et al. (29) | 5 | PTV = entire tumor + 5 mm | 35 Gy | TVI (margin-directed boost) | 50 Gy |
| Kharofa et al. (30) | 5 | PTV elective = PTV + customized nodal space and mesenteric vessels | 25 Gy | PTV = GTV + TVI | 33 Gy |
| Koay EJ et al. (31) | 5 | PTV = (GTV + TVI) + 3 mm | 33 Gy | PTV_high = PTV with PRV OARs subtracted | 50 Gy |
| Simoni et al. (32) | 5 | PTV = entire tumor + 5 mm | 30 Gy | TVI (region of vessel abutment/encasement) | 50 Gy |

n, number; PTV, planning target volume; SIB, simultaneous integrated boost; Gy, gray; TVI, tumor-vessel interface; GTV, gross tumor volume; PM, posterior margin; PRV OARs, planning organs at risk volume.
DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because the datasets generated for this study are available on request to the corresponding author, subject to approval by the Institutional Review Board. Requests to access the datasets should be directed to nicola.simoni@aovr.veneto.it.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comitato etico per la Sperimentazione Clinica (CESC) delle Province di Verona e Rovigo. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

1. Hammel P, Huguet F, van Laethem JL, Goldstein D, Gilmeilus B, Artru P, et al. Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic Cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA (2016) 315:1844–53. doi: 10.1001/jama.2016.4324

2. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst (1988) 80:751–5. doi: 10.1093/jnci/80.10.751

3. Loehrer PS Jr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 29:4105–12. doi: 10.1200/JCO.2011.34.8904

4. Klaassen DJ, Macntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol (1985) 3:373–8. doi: 10.1200/JCO.1985.3.3.373

5. Chauvet B, Monnex F, Bonnetain F, Rousset P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCDF/SFRO study. Ann Oncol (2008) 19:1592–9. doi: 10.1093/annonc/mdn281

6. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 27:1806–13. doi: 10.1200/JCO.2008.17.7188

7. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javel MM, Hobbs BD, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol (2011) 29:3037–43. doi: 10.1200/JCO.2010.33.8038

8. de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancis JD, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer (2017) 123:4158–67. doi: 10.1002/cncr.30856

9. Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer (2017) 123:3486–93. doi: 10.1002/cncr.30706

10. Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRISP): An international systematic review and meta-analysis. Cancer (2020) 126:2120–31. doi: 10.1002/cncr.32750

11. Arcelli A, Guido A, Buwenge M, Simoni N, Mazzarotto R, Macchia G, et al. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Anticancer Res (2020) 40:465–72. doi: 10.21873/anticancer.13975

12. Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol (2013) 8:254. doi: 10.1186/1748-717X-8-254

13. Moningi S, Dholakia AS, Raman SP, Blackard A, Cameron JL, Le DT, et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol (2015) 22:2352–8. doi: 10.1245/s10434-014-4274-5

14. Suker M, Nuyttens JJ, Eskens FALM, Haberkorn BC, Coene PPL0, Van Der Harst E, et al. Efficacy and feasibility of stereotactic radiotherapy after foltinrix in patients with locally advanced pancreatic cancer (LAPC-1 trial). EclinicalMedicine (2019) 19(17):100200. doi: 10.1016/j.eclinm.2019.10.013

15. Simoni N, Micerà R, Païella S, Guariglia S, Zivelonghi E, Malleo G, et al. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Clin Oncol (R Coll Radiol) (2020) S0936-6552(20)30275-2. doi: 10.1016/j.jcloc.2020.06.019

16. Oar A, Lee M, Le H, Hruby G, Dalsen R, Pryor D, et al. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Transman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol (2020) 10:e136–46. doi: 10.1016/j.prro.2019.07.018

17. Colbert LE, Rebueno N, Moni S, Beddar S, Sawakuchi GO, Herman JM, et al. Dose escalation for locally advanced pancreatic cancer: How high can we go? Adv Radiat Oncol (2018) 3:693–706. doi: 10.1016/j.adro.2018.07.008

18. Palta M, Godfrey D, Goodman KA, Hoefle S, Dawson LA, Dessert D, et al. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol (2019) 9:322–32. doi: 10.1016/j.prro.2019.06.016

19. Bernard V, Herman JM. Pancreas SBRT: Who, What, Where, and How… Pract Radiat Oncol (2020) 10:183–5. doi: 10.1016/j.prro.2019.11.005

20. Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, et al. Phase II randomized controlled trial. JAMA Oncol (2018) 4:655–60. doi: 10.1001/jamaoncol.2018.3091

21. Lovelock DM, Zaky J, Goodman K, Yamada Y, Dawson LA, Dessert D, et al. The effectiveness of a pneumatic compression belt in reducing respiratory motion of abdominal tumors in patients undergoing stereotactic body radiation. Technol Cancer Res Treat (2004) 3:259–67. doi: 10.1016/j.prro.2019.06.016

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.600940/full#supplementary-material

AUTHOR CONTRIBUTIONS

Conceptualization, RMa and NS. Methodology, NS and SG. Validation, GR, RMI, GM, and SP. Plan study and preparation, SG, AP, and EZ. Plan evaluation, NS, GR, and RMI. Writing—original draft preparation, NS and SG. Writing—review and editing, RMI, EZ, and CC. Images curation: NS and RD. All authors contributed to the article and approved the submitted version.

Mazzarotto et al. SBRT Dose Escalation in LAPC
22. Campbell WG, Jones BL, Scheffer T, Goodman KA, Miften M. An evaluation of motion mitigation techniques for pancreatic SBRT. *Radiother Oncol* (2017) 124:168–73. doi: 10.1016/j.radonc.2017.05.013

23. Forbang Teboh R, Srinivasan S, Ng SP, Aliru ML, Herman JM. Setup Management for Stereotactic Body Radiation Therapy of Patients With Pancreatic Cancer Treated via the Breath-Hold Technique. *Pract Radiat Oncol* (2020) 10:e280–9. doi: 10.1016/j.prro.2019.10.012

24. Fujimoto K, Shinoki T, Yuasa Y, Onizuka R, Yamane M. Evaluation of the effects of motion mitigation strategies on respiration-induced motion in each pancreatic region using cine-magnetic resonance imaging. *J Appl Clin Med Phys* (2019) 20:42–50. doi: 10.1002/acm2.12693

25. Placidi L, Romano A, Chiloiro G, Cusumano D, Boldrini L, Cellini F, et al. Online adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations. *Tech Innov Patient Support Radiat Oncol* (2020) 15:15–21. doi: 10.1016/j.tipsro.2020.06.001

26. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. *Int J Radiat Oncol Biol Phys* (2013) 86:516–22. doi: 10.1016/j.ijrobp.2013.02.022

27. Mellon EA, Hofse SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. *Acta Oncol* (2015) 54:979–85. doi: 10.3109/0284186X.2015.1004567

28. Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, et al. A Phase I Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). *Int J Radiat Oncol Biol Phys* (2016) 96:296–303. doi: 10.1016/j.ijrobp.2016.05.010

29. Holyoake DLP, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, et al. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the ‘SPARC’ trial protocol. *BMC Cancer* (2016) 16:728. doi: 10.1186/s12885-016-2765-4

30. Kharofa J, Mierwia M, Olowokure O, Sussman J, Latif T, Gupta A, et al. Pattern of marginal local failure in a phase ii trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer. *Am J Clin Oncol* (2019) 42:247–52. doi: 10.1097/COC.0000000000000518

31. Koay EJ, Hanania AN, Hall WA, Taniguchi CM, Rebuono N, Myrehaug S, et al. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. *Pract Radiat Oncol* (2020) 13: S1879–8500(20)30035-7. doi: 10.1016/j.prro.2020.01.012

32. Caravatta L, Cellini F, Simonelli R, Rosa C, Niespolo MR, Lupatelli M, et al. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers. *Acta Oncol* (2019) 58:439–47. doi: 10.1080/0284186X.2018.1546899

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a past co-authorship with several of the authors RM, NS.

Copyright © 2020 Mazzarotto, Simonelli, Guariglia, Rossi, Micera, De Robertis, Pierelli, Zivelonghi, Malles, Paiella, Savina, Cavedon, Milella and Bassi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.